TMO Share Price Performance
US$448.21
43.28 (10.69%)
13.8% undervalued intrinsic discount
US$520.00
Fair Value
Price US$448.21
AnalystLowTarget US$520.00
AnalystConsensusTarget US$648.28
Unike US$540.27
Fair ValueUS$520.00
Share Pricen/a
Thermo Fisher Scientific Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 224 Fair Values set on narratives written by author
TMO Community Narratives
AN
Fair Value
·Fair Value US$520 13.8% undervalued intrinsic discount
US China Tensions And Trade Restrictions Will Impair Margins
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$648.28 30.9% undervalued intrinsic discount
Life Science Leadership And Pharma Partnerships Will Drive Long-Term Market Momentum
0users have liked this narrative
0users have commented on this narrative
80users have followed this narrative
UN
Fair Value
·Fair Value US$540.27 17.0% undervalued intrinsic discount
The demand for personalized medicine will keep Thermo Fisher Scientific thriving
1users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
The demand for personalized medicine will keep Thermo Fisher Scientific thriving
Thermo Fisher sells the tools and services that drugmakers and research labs rely on, and the shift toward more tailored treatments keeps that demand growing. The bigger question is whether fading pandemic-era sales and tighter biotech funding slow things down, or whether its steady, repeat business and past deals help it keep moving forward.Read more
US China Tensions And Trade Restrictions Will Impair Margins
Key Takeaways Heightened geopolitical tensions, cost control measures, and changing industry dynamics are likely to pressure margins and limit meaningful global growth for Thermo Fisher. Heavy reliance on acquisitions and exposure to disruptive technologies present ongoing risks to revenue stability and the firm's long-term market leadership.Read more
AN
US$520
13.8% undervalued intrinsic discount
Fair Value
Revenue
5.8% p.a.
Profit Margin
15.66%
Future PE
28x
Price in 2029
US$659.24
Life Science Leadership And Pharma Partnerships Will Drive Long-Term Market Momentum
Key Takeaways Expansion in pharmaceutical manufacturing, innovation in analytical tools, and end-to-end customer integration drive robust, recurring revenue and strengthen competitive positioning. Cost discipline, AI-driven efficiency, and strategic acquisitions support higher margins and sustainable returns despite fluctuating market demand.Read more
AN
US$648.28
30.9% undervalued intrinsic discount
Fair Value
Revenue
6.07% p.a.
Profit Margin
17.8%
Future PE
30.8x
Price in 2029
US$823.32
Aging Populations And Gene Therapies Will Drive Precision Medicine
Key Takeaways Industry-leading innovation, strategic acquisitions, and operational excellence position Thermo Fisher to gain market share and expand margins ahead of competitors as demand for advanced bioprocessing surges. Demographic shifts and rising global demand for cutting-edge healthcare solutions set the stage for sustained earnings growth, broadened market presence, and a widening competitive moat.Read more
AN
US$738.42
39.3% undervalued intrinsic discount
Fair Value
Revenue
7.85% p.a.
Profit Margin
17.67%
Future PE
33.61x
Price in 2029
US$937.72
Trending Discussion
Recently Updated Narratives
UN
The demand for personalized medicine will keep Thermo Fisher Scientific thriving
Fair Value: US$540.27 17.0% undervalued intrinsic discount
24 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TMO: Revised Profitability And Tools Headwinds Will Shape Returns Through 2026
Fair Value: US$520 13.8% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TMO: 2026 Tools Demand And New Platforms Will Drive Performance
Fair Value: US$648.28 30.9% undervalued intrinsic discount
80 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Thermo Fisher Scientific Inc. Key Details
Last Reported Earnings
Mar 28, 2026
Next Reporting Earnings
n/a
- 18.43
- 40.93%
- 15.15%
- 82.5%
About TMO
- Founded
- 1956
- Employees
- 125000
- CEO
- WebsiteView website
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
